D-0116-2025 Class II Terminated

Recalled by Mckesson Medical-Surgical Inc. Corporate Office — Richmond, VA

FDA drug recall D-0116-2025 was initiated by Mckesson Medical-Surgical Inc. Corporate Office on September 11, 2024 and is designated Class II. Reason for recall: cGMP Deviations: Temperature excursion The recall status is terminated (terminated August 20, 2025). Affected quantity: 5 cartons/20 units each carton.

Recall Details

Product Type
Drugs
Report Date
December 18, 2024
Initiation Date
September 11, 2024
Termination Date
August 20, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
5 cartons/20 units each carton

Product Description

Hylenex recombinant (hyaluronidase) injection, 150 USP units/mL, 4x1 mL Single Dose Vials, Rx only, Manufactured for and marketed by Halozyme, Inc., 12390 El Camino Real San Diego California 92130, Distributed by Antares Pharma, Inc., Ewing, NJ NDC 18657-117-04

Reason for Recall

cGMP Deviations: Temperature excursion

Distribution Pattern

Virgina

Code Information

Serial # 100000831961 100000820688 100000820689 100000820515